1. Home
  2. APVO
  3. APVO News

Latest Aptevo Therapeutics Inc. (APVO) News on June 29, 2025

Aptevo announces addition of preclinical candidate APVO455 to portfolio
APVO

TipRanks

8 days ago

Aptevo announces addition of preclinical candidate APVO455 to portfolio

APVO

MT Newswires

9 days ago

Aptevo Closes $8 Million Offering of Stock, Warrants; Shares Fall

APVO

MT Newswires

11 days ago

Top Midday Gainers

APVO

MT Newswires

11 days ago

Aptevo Therapeutics Launches $8 Million Offering

APVO

ACCESS Newswire

11 days ago

Aptevo Therapeutics Announces $8 Million Offering Priced At-the-Market Under Nasdaq Rules

APVO

MT Newswires

11 days ago

Aptevo Says Its Mipletamig Therapy Achieves 85% Remission Rate in Leukemia Patients; Shares Soar Pre-Bell

APVO

ACCESS Newswire

11 days ago

Mipletamig Demonstrates Compelling Clinical Activity in Frontline AML

APVO

ACCESS Newswire

16 days ago

Aptevo Participating in the BIO International Convention

APVO

ACCESS Newswire

a month ago

Aptevo Therapeutics Announces 1-for-20 Reverse Stock Split as part of Nasdaq Compliance Plan

APVO

ACCESS Newswire

a month ago

Aptevo Therapeutics Reports 1Q25 Financial Results And Provides an Update on Mipletamig

APVO

ACCESS Newswire

2 months ago

Aptevo Therapeutics Provides Program Update for Bispecific APVO711, a PD-L1 X CD40 that Combines a Checkpoint Inhibitor and Immune Activation

APVO

ACCESS Newswire

2 months ago

Aptevo Therapeutics Announces the Closing of $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

APVO

ACCESS Newswire

2 months ago

Aptevo Therapeutics $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

APVO

ACCESS Newswire

3 months ago

Aptevo Therapeutics Announces the Closing of $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

APVO

ACCESS Newswire

3 months ago

Aptevo Therapeutics $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

Aptevo Therapeutics Says Two Additional Patients In Early-Stage Leukemia Trial Achieve Remission Within 30 Days of Treatment
APVO

Benzinga

3 months ago

Aptevo Therapeutics Says Two Additional Patients In Early-Stage Leukemia Trial Achieve Remission Within 30 Days of Treatment

APVO

ACCESS Newswire

3 months ago

RAINIER Trial Data Update: Two Additional AML Patients Achieve Remission Within 30 Days of Treatment

APVO

ACCESS Newswire

3 months ago

Aptevo Highlights APVO603: A Novel Bispecific Antibody Targeting 4-1BB and OX40 for Enhanced Solid Tumor Immunotherapy

APVO

ACCESS Newswire

4 months ago

Aptevo to Participate in March Conferences

Aptevo Therapeutics Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
APVO

ACCESS Newswire

4 months ago

Aptevo Therapeutics Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

APVO

ACCESS Newswire

4 months ago

Aptevo Therapeutics Reports 2024 Financial Results And Provides A Business Update

APVO

ACCESS Newswire

5 months ago

Aptevo's Peter Pavlik, PhD, Chairing Session on "Bi and Multispecific Biologics" at Cambridge Healthcare Institute's Pep Talk 2025

APVO

ACCESSWIRE

7 months ago

Aptevo Therapeutics Announces Exercise of Warrants for $6.2 Million Gross Proceeds

APVO

ACCESSWIRE

7 months ago

100% of Patients Achieve Remission Within 30 Days in Cohort 1 of Bispecific Mipletamig Frontline AML Trial

APVO

ACCESSWIRE

7 months ago

Bispecific Antibody, APVO442, Differentiated to Treat Prostate Cancer with Precision Tumor Targeting and Reduced Risk of Side Effects

APVO

ACCESSWIRE

7 months ago

Aptevo Therapeutics Announces 1-for 37 Reverse Stock Split As Part of Nasdaq Compliance Plan

APVO

ACCESSWIRE

7 months ago

Proving the Concept: Aptevo Technology, Pipeline, to Exemplify the Speed and Power of Modular Biotherapeutics at Presentation

APVO

ACCESSWIRE

7 months ago

Aptevo Highlights the Potential of the Company's Robust Portfolio in Cancer Immunotherapy, the Success of Bispecifics as a Category, and Their Growing Importance in the Oncology Treatment Paradigm

APVO

ACCESSWIRE

7 months ago

First Patient Dosed in Aptevo's Ongoing RAINIER Trial Achieves 90% Reduction in Leukemic Blasts Within the First 30 Days of Treatment, Continues Overall Efficacy Trend Seen in Prior Mipletamig AML Studies

APVO

ACCESSWIRE

8 months ago

First-in-Class Bispecific Antibody, ALG.APV-527, Meets Important Trial Endpoints in Phase 1 Solid Tumor Trial

APVO

ACCESSWIRE

8 months ago

Aptevo Therapeutics Reports 3Q 2024 Financial Results and Provides a Business Update

APVO

ACCESSWIRE

8 months ago

Aptevo Therapeutics and Alligator Bioscience to Present Additional Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types, at SITC 2024

Aptevo Therapeutics Announces Closing of $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules
APVO

ACCESSWIRE

9 months ago

Aptevo Therapeutics Announces Closing of $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules

Aptevo Therapeutics Announces $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules
APVO

ACCESSWIRE

9 months ago

Aptevo Therapeutics Announces $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules

Aptevo Therapeutics and Alligator Bioscience Announce Data from Phase 1 ALG.APV-527 Monotherapy Trial Showing 60% of Evaluable Patients Achieved Stable Disease in Solid Tumor Study
APVO

ACCESSWIRE

9 months ago

Aptevo Therapeutics and Alligator Bioscience Announce Data from Phase 1 ALG.APV-527 Monotherapy Trial Showing 60% of Evaluable Patients Achieved Stable Disease in Solid Tumor Study

Aptevo Therapeutics and Alligator Bioscience to Present Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types, at ESMO Congress 2024
APVO

ACCESSWIRE

10 months ago

Aptevo Therapeutics and Alligator Bioscience to Present Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types, at ESMO Congress 2024

Phase 1b/2 "RAINIER" Frontline Acute Myeloid Leukemia (AML) Trial Initiated
APVO

ACCESSWIRE

a year ago

Phase 1b/2 "RAINIER" Frontline Acute Myeloid Leukemia (AML) Trial Initiated

Aptevo Therapeutics Reports 2Q 2024 Financial Results and Provides a Business Update
APVO

ACCESSWIRE

a year ago

Aptevo Therapeutics Reports 2Q 2024 Financial Results and Provides a Business Update

Aptevo Therapeutics Announces Closing of $2.75 Million Offering
APVO

ACCESSWIRE

a year ago

Aptevo Therapeutics Announces Closing of $2.75 Million Offering

Aptevo Therapeutics Announces $2.75 Million Offering Priced At-the-Market Under Nasdaq Rules
APVO

ACCESSWIRE

a year ago

Aptevo Therapeutics Announces $2.75 Million Offering Priced At-the-Market Under Nasdaq Rules

Aptevo Participating in the BIO International Convention
APVO

ACCESSWIRE

a year ago

Aptevo Participating in the BIO International Convention

Aptevo Therapeutics Presenting at The Protein & Antibody Engineering Summit, Boston, MA
APVO

ACCESSWIRE

a year ago

Aptevo Therapeutics Presenting at The Protein & Antibody Engineering Summit, Boston, MA

Aptevo Therapeutics Reports 1Q 2024 Financial Results and Provides a Business Update
APVO

ACCESSWIRE

a year ago

Aptevo Therapeutics Reports 1Q 2024 Financial Results and Provides a Business Update

Aptevo Therapeutics Announces Closing of $4.6 Million Public Offering
APVO

ACCESSWIRE

a year ago

Aptevo Therapeutics Announces Closing of $4.6 Million Public Offering

Aptevo Therapeutics Announces Pricing of $4.6 Million Public Offering
APVO

ACCESSWIRE

a year ago

Aptevo Therapeutics Announces Pricing of $4.6 Million Public Offering

Aptevo Therapeutics Provides Pipeline Update
APVO

ACCESSWIRE

a year ago

Aptevo Therapeutics Provides Pipeline Update

Aptevo Participating in The Springtime Partnering Event, a Bio-Europe Conference
APVO

ACCESSWIRE

a year ago

Aptevo Participating in The Springtime Partnering Event, a Bio-Europe Conference

Alligator Bioscience and Aptevo Therapeutics Announce Positive Interim Data of Dose Escalation Phase of ALG.APV-527 Phase 1 Study in Solid Tumor Cancers Expressing Tumor Antigen 5T4
APVO

ACCESSWIRE

a year ago

Alligator Bioscience and Aptevo Therapeutics Announce Positive Interim Data of Dose Escalation Phase of ALG.APV-527 Phase 1 Study in Solid Tumor Cancers Expressing Tumor Antigen 5T4

Aptevo Therapeutics Reports 2023 Financial Results and Provides a Business Update
APVO

ACCESSWIRE

a year ago

Aptevo Therapeutics Reports 2023 Financial Results and Provides a Business Update

Aptevo Therapeutics Announces 1-for 44 Reverse Stock Split As Part of Nasdaq Compliance Plan
APVO

ACCESSWIRE

a year ago

Aptevo Therapeutics Announces 1-for 44 Reverse Stock Split As Part of Nasdaq Compliance Plan

APVO

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 02/01/2024

APVO

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 01/31/2024

Greenwave Technology Solutions' Scrap App Continues Capturing Market Share
APVO

PR Newswire

a year ago

Greenwave Technology Solutions' Scrap App Continues Capturing Market Share

180 Degree Capital Corp. Nominates Matthew F. McLaughlin for Election to the Board of comScore, Inc.
APVO

GlobeNewswire

a year ago

180 Degree Capital Corp. Nominates Matthew F. McLaughlin for Election to the Board of comScore, Inc.

FAT Brands Foundation Awards Over $250,000 to Local Non-Profits in 2023
APVO

GlobeNewswire

a year ago

FAT Brands Foundation Awards Over $250,000 to Local Non-Profits in 2023

Visionary Education Group Established a MOU with Algoma University
APVO

PR Newswire

a year ago

Visionary Education Group Established a MOU with Algoma University

Toro Corp. Announces the Completion of the Sale of the M/T Wonder Sirius
APVO

GlobeNewswire

a year ago

Toro Corp. Announces the Completion of the Sale of the M/T Wonder Sirius

RF Industries, Ltd. (NASDAQ:RFIL) Q4 2023 Earnings Call Transcript
APVO

Insider Monkey

a year ago

RF Industries, Ltd. (NASDAQ:RFIL) Q4 2023 Earnings Call Transcript

Keen Vision Acquisition Corporation (NASDAQ:KVAC) most popular amongst retail investors who own 45% of the shares, institutions hold 32%
APVO

Simply Wall St.

a year ago

Keen Vision Acquisition Corporation (NASDAQ:KVAC) most popular amongst retail investors who own 45% of the shares, institutions hold 32%

APVO

Thomson Reuters StreetEvents

a year ago

Q4 2023 RF Industries Ltd Earnings Call

RF Industries Reports Fourth Quarter and Fiscal Year 2023 Financial Results
APVO

ACCESSWIRE

a year ago

RF Industries Reports Fourth Quarter and Fiscal Year 2023 Financial Results

Urgently Secures Engagement with Global Top 5 Automotive OEM
APVO

GlobeNewswire

a year ago

Urgently Secures Engagement with Global Top 5 Automotive OEM

Lipocine and Verity Pharma Enter into License Agreement for TLANDO® Franchise in the U.S. and Canada
APVO

PR Newswire

a year ago

Lipocine and Verity Pharma Enter into License Agreement for TLANDO® Franchise in the U.S. and Canada

Northann Corp. Receives Approval from U.S. Patent and Trademark Office for Core Technology in Benchwick 3D Printing Ecosystem
APVO

GlobeNewswire

a year ago

Northann Corp. Receives Approval from U.S. Patent and Trademark Office for Core Technology in Benchwick 3D Printing Ecosystem

Toro Corp. Announces the Sale of the M/T Wonder Sirius for $33.8 Million with an Expected Net Gain of $20.9 Million
APVO

GlobeNewswire

a year ago

Toro Corp. Announces the Sale of the M/T Wonder Sirius for $33.8 Million with an Expected Net Gain of $20.9 Million

LiveOne (Nasdaq: LVO) Provides Update for Its $10M Stock Repurchase Program
APVO

GlobeNewswire

a year ago

LiveOne (Nasdaq: LVO) Provides Update for Its $10M Stock Repurchase Program

DiaMedica Therapeutics Inc.'s (NASDAQ:DMAC) largest shareholders are individual investors with 52% ownership, insiders own 37%
APVO

Simply Wall St.

a year ago

DiaMedica Therapeutics Inc.'s (NASDAQ:DMAC) largest shareholders are individual investors with 52% ownership, insiders own 37%

17EdTech Has Regained Compliance with Nasdaq’s Minimum Bid Price Requirement
APVO

GlobeNewswire

a year ago

17EdTech Has Regained Compliance with Nasdaq’s Minimum Bid Price Requirement

Apollomics Completes Patient Enrollment for Phase 3 Trial of Leukemia Treatment
APVO

Exec Edge

a year ago

Apollomics Completes Patient Enrollment for Phase 3 Trial of Leukemia Treatment

Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia
APVO

GlobeNewswire

a year ago

Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia

Precipio Announces Christina Valauri joins the Board of Directors
APVO

GlobeNewswire

a year ago

Precipio Announces Christina Valauri joins the Board of Directors

Trust Stamp has partnered with Scurid to deliver highly secure, AI-powered in-field authentication for seamless human-machine interaction
APVO

GlobeNewswire

2 years ago

Trust Stamp has partnered with Scurid to deliver highly secure, AI-powered in-field authentication for seamless human-machine interaction

Zhongchao First Half 2023 Earnings: US$0.18 loss per share (vs US$0.004 profit in 1H 2022)
APVO

Simply Wall St.

2 years ago

Zhongchao First Half 2023 Earnings: US$0.18 loss per share (vs US$0.004 profit in 1H 2022)

Cenntro Regains Compliance with Nasdaq Minimum Bid Price Rule
APVO

Business Wire

2 years ago

Cenntro Regains Compliance with Nasdaq Minimum Bid Price Rule

Insider Buying: CEO Steven Lisi Acquires 77,775 Shares of Beyond Air Inc
APVO

GuruFocus.com

2 years ago

Insider Buying: CEO Steven Lisi Acquires 77,775 Shares of Beyond Air Inc

PodcastOne (NASDAQ: PODC) Acquires Exclusive Rights to Hit Podcast Was I In A Cult? From Hosts Liz Iacuzzi and Tyler Measom
APVO

GlobeNewswire

2 years ago

PodcastOne (NASDAQ: PODC) Acquires Exclusive Rights to Hit Podcast Was I In A Cult? From Hosts Liz Iacuzzi and Tyler Measom

Addex Shareholders Approve All Resolutions at Extraordinary General Meeting
APVO

GlobeNewswire

2 years ago

Addex Shareholders Approve All Resolutions at Extraordinary General Meeting

PRINCIPAL REAL ESTATE INCOME FUND CONTINUES SHARE REPURCHASE PROGRAM
APVO

PR Newswire

2 years ago

PRINCIPAL REAL ESTATE INCOME FUND CONTINUES SHARE REPURCHASE PROGRAM

Linkage Global Inc Announces Pricing of $6,000,000 Initial Public Offering
APVO

GlobeNewswire

2 years ago

Linkage Global Inc Announces Pricing of $6,000,000 Initial Public Offering

NCS Multistage Holdings, Inc. Settles Outstanding Commercial Litigation with No Cash Payment By Company
APVO

GlobeNewswire

2 years ago

NCS Multistage Holdings, Inc. Settles Outstanding Commercial Litigation with No Cash Payment By Company

Presto’s Voice™ AI Solution Projected to Capitalize on Strong Momentum as Company Releases 2024 Projected Annualized Run Rate
APVO

GlobeNewswire

2 years ago

Presto’s Voice™ AI Solution Projected to Capitalize on Strong Momentum as Company Releases 2024 Projected Annualized Run Rate

HomeTrust Bancshares (HTBI) Soars 5.4%: Is Further Upside Left in the Stock?
APVO

Zacks

2 years ago

HomeTrust Bancshares (HTBI) Soars 5.4%: Is Further Upside Left in the Stock?

APVO

PR Newswire

2 years ago

Zhongchao Inc. Collaborates with a Public Health Foundation to Support Sustainable and Effective Cancer Treatments

MicroAlgo Inc. announced plans to establish a practice base to train graduate students for the university
APVO

PR Newswire

2 years ago

MicroAlgo Inc. announced plans to establish a practice base to train graduate students for the university

Biotech Stock Roundup: RNA Up on BMY Deal Expansion, BIVI Down on Setback & More
APVO

Zacks

2 years ago

Biotech Stock Roundup: RNA Up on BMY Deal Expansion, BIVI Down on Setback & More

Senstar Technologies Reports Third Quarter 2023 Financial Results
APVO

PR Newswire

2 years ago

Senstar Technologies Reports Third Quarter 2023 Financial Results

Duluth Holdings Inc (DLTH) Reports Q3 2023 Financial Results Amidst Challenging Retail Environment
APVO

GuruFocus.com

2 years ago

Duluth Holdings Inc (DLTH) Reports Q3 2023 Financial Results Amidst Challenging Retail Environment

Investors in HomeTrust Bancshares (NASDAQ:HTBI) have seen returns of 27% over the past three years
APVO

Simply Wall St.

2 years ago

Investors in HomeTrust Bancshares (NASDAQ:HTBI) have seen returns of 27% over the past three years

PAVmed Inc. (NASDAQ:PAVM) Q3 2023 Earnings Call Transcript
APVO

Insider Monkey

2 years ago

PAVmed Inc. (NASDAQ:PAVM) Q3 2023 Earnings Call Transcript

MAIA Biotechnology Announces Closing of $4 Million Registered Direct Offering
APVO

Business Wire

2 years ago

MAIA Biotechnology Announces Closing of $4 Million Registered Direct Offering

Beyond Air® To Participate in the 35th Annual Piper Sandler Healthcare Conference
APVO

GlobeNewswire

2 years ago

Beyond Air® To Participate in the 35th Annual Piper Sandler Healthcare Conference

GOLD ROYALTY REPORTS THIRD QUARTER 2023 FINANCIAL AND OPERATING RESULTS - CONTINUED GROWTH DRIVEN BY RECENT ACQUISITIONS
APVO

PR Newswire

2 years ago

GOLD ROYALTY REPORTS THIRD QUARTER 2023 FINANCIAL AND OPERATING RESULTS - CONTINUED GROWTH DRIVEN BY RECENT ACQUISITIONS

Intellinetics Grows Revenues 10% in Q3 2023; 27% Year-to-Date
APVO

Business Wire

2 years ago

Intellinetics Grows Revenues 10% in Q3 2023; 27% Year-to-Date

Aptevo Therapeutics Reports 3Q23 Financial Results and Provides a Business Update
APVO

ACCESSWIRE

2 years ago

Aptevo Therapeutics Reports 3Q23 Financial Results and Provides a Business Update

Ocean Biomedical (NASDAQ: OCEA) Announces Positive Preclinical Oncology Data for VRON-0300, Presented at SITC 2023 Annual Meeting, and Clinical Updates by 50/50 Joint Venture Partner Virion Therapeutics
APVO

GlobeNewswire

2 years ago

Ocean Biomedical (NASDAQ: OCEA) Announces Positive Preclinical Oncology Data for VRON-0300, Presented at SITC 2023 Annual Meeting, and Clinical Updates by 50/50 Joint Venture Partner Virion Therapeutics

Kronos Bio, Inc. (KRON) Reports Q3 Loss, Lags Revenue Estimates
APVO

Zacks

2 years ago

Kronos Bio, Inc. (KRON) Reports Q3 Loss, Lags Revenue Estimates

LightPath Technologies, Inc. (NASDAQ:LPTH) Q1 2024 Earnings Call Transcript
APVO

Insider Monkey

2 years ago

LightPath Technologies, Inc. (NASDAQ:LPTH) Q1 2024 Earnings Call Transcript

Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Q3 2023 Earnings Call Transcript
APVO

Insider Monkey

2 years ago

Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Q3 2023 Earnings Call Transcript

APVO

Thomson Reuters StreetEvents

2 years ago

Q1 2024 LightPath Technologies Inc Earnings Call

APVO

Thomson Reuters StreetEvents

2 years ago

Q3 2023 Lineage Cell Therapeutics Inc Earnings Call

Share on Social Networks: